# Tempus AI (TEM) investment thesis

By Clearthesis. Data as of November 3, 2026. Written November 3, 2026. Full page: https://www.clearthesis.ai/thesis/TEM?utm_source=ai_agent&utm_medium=markdown

Tempus AI is a healthcare technology business that uses artificial intelligence and genomic sequencing to customize cancer treatments and help pharmaceutical companies discover new drugs.

The question investors are asking: Tempus AI has recently reached adjusted profitability and is expanding rapidly into new medical fields like cardiology. Can it become the essential data platform for all of medicine, or will high laboratory costs and data regulations cap its potential?

## Summary

Tempus runs a high-growth diagnostic platform that is successfully converting a massive library of patient data into high-margin licensing revenue. The key constraint is the high cost of laboratory operations, which requires consistent volume growth to reach full-scale profitability.

## The thesis in brief

- Tempus AI uses artificial intelligence and genomic sequencing to help doctors choose the right treatments for patients, primarily in oncology and cardiology. It generated $1.51 billion in revenue over the last twelve months, which grew 83.4% in the last fiscal year as it scaled its massive library of clinical and molecular data.
- The company's real power comes from its multimodal data library, which integrates patient records with genetic tests to create a map of how different cancers respond to drugs. Pharmaceutical companies pay hundreds of millions to access this library because it helps them design better clinical trials and discover new drugs faster than they could on their own.
- The next phase of growth depends on the acquisition of Personalis, which adds minimal residual disease testing to the platform for monitoring cancer recurrence. This move, alongside two new FDA clearances for heart-related AI tools, signals that Tempus is successfully moving beyond its oncology roots into a broader healthcare technology ecosystem.
- The primary risk is the high concentration of revenue from related parties like Pathos AI, which suggests some demand may not be at arm's length. We lean positive on the business because it has reached adjusted profitability ahead of schedule, proving its model can sustain itself while maintaining 30% volume growth.

- Tempus AI is a healthcare technology business that uses AI to customize patient treatments and drug discovery.
- The growth driver is the expansion into new diseases like cardiology and the acquisition of Personalis for cancer monitoring.
- It reached adjusted profitability this quarter, proving its high-margin data licensing can offset laboratory costs.
- We lean positive: the company is successfully transitioning from a cash-burning lab to a self-sustaining data platform.

## The business

- Stage: Hypergrowth

What does it do? Tempus AI is a hypergrowth healthcare technology business that earns money by selling advanced genetic tests and licensing the resulting patient data to pharmaceutical companies. When a doctor orders a Tempus test for a cancer patient, the company sequences the patient's DNA and uses AI to compare it against its massive library of millions of clinical records. This helps the doctor pick the most effective treatment based on how similar patients responded in the past. Beyond the clinic, Tempus de-identifies this data and sells access to it through its Lens platform, where drug researchers pay for insights that accelerate their own development work.

Where does revenue come from? Revenue is split between Diagnostics, which sells the actual lab tests, and Data & Applications, which licenses the platform's insights. The Diagnostics segment brings in the majority of revenue (74%) by charging insurance companies and health systems for sequencing and pathology services. Data & Applications (26%) earns high-margin fees from pharmaceutical companies through multi-year licensing deals and strategic research partnerships.

Who are its customers? Tempus AI serves over 7,000 oncologists and nearly all of the top 20 global pharmaceutical companies. In the latest quarter, the company saw oncology unit volume grow 32%, with its minimal residual disease (MRD) test volume surging 300% to 12,000 tests as adoption of monitoring tools increases. The data business is fueled by massive contracts, including a $137.5 million licensing deal with Bristol-Myers Squibb and over $550 million in total data bookings year-to-date. However, a significant portion of data revenue currently comes from Pathos AI, a related party that accounted for $22.1 million (over 20%) of segment revenue this quarter.

What gives it staying power? The library of multimodal data becomes a barrier to entry because it is built on years of direct integration with hospital workflows. A new competitor would need to not only build the lab infrastructure but also spend years convincing doctors to share the clinical outcomes data that makes the AI models effective.

Where is it headed? Tempus is making a massive strategic bet on cardiology and personalized cancer vaccines. By securing new FDA clearances for heart-monitoring AI and partnering with Merck and Moderna on neoantigen therapies, the company is aiming to become the standard data layer for all precision medicine, not just oncology.

## Financial performance

Tempus AI is showing strong top-line momentum, with revenue growing 23.1% in the latest quarter to $411.5 million. While growth has decelerated from the 83.4% seen last fiscal year, the company's oncology unit volume is actually accelerating at 32% year-over-year.

The business reached a major milestone this quarter by delivering $25.6 million in Adjusted EBITDA, turning profitable on an adjusted basis ahead of our previous expectations. However, the first 'profitable' non-GAAP quarter was helped by a $42.8 million unrealized gain on marketable securities, which masked a $56.9 million operating loss.

The balance sheet is relatively strong with $854.4 million in cash and marketable securities, providing enough cushion to fund the pending acquisition of Personalis. With free cash flow margins at -4.4% over the last twelve months, the company is rapidly closing the gap to self-sustainability.

Tempus AI is a business in a successful transition from a high-burn diagnostic lab to a high-margin data platform that is now proving it can generate positive adjusted cash flow.

- Dividend note: Tempus AI does not pay a dividend and has no history of buying back stock, as it remains focused on reinvesting all available capital into growth and acquisitions. The company currently uses its cash to fund research and development and to acquire complementary technologies like Personalis to expand its data moat. Because the share count has remained relatively stable since the IPO, owners have not seen their stake diluted by major secondary offerings, but they should not expect cash returns in the near term.

- Last quarter note: In Q3 FY2026, Tempus reported revenue of $411.5 million and non-GAAP EPS of $0.07, representing 23.1% revenue growth and a significant swing to adjusted profitability. This result signals that the high-margin data business is successfully beginning to offset the heavy fixed costs of the laboratory operations.

What's working well? Oncology unit volume growth is accelerating, with a 32% increase this quarter proving that the core diagnostic platform is still gaining massive market share. This volume growth is critical because every new test performed adds another patient record to the data library, strengthening the moat for the licensing business.

What to watch? Related-party revenue concentration is a growing concern, as Pathos AI accounted for over 20% of the data and applications segment this quarter. Investors must monitor whether Tempus can continue to sign large deals with outside pharmaceutical companies like the $137.5 million BMS contract to prove that market demand is broader than its own corporate affiliates.

## Moat and competition

- Moat: Narrow
- Moat why: Revenue concentration in related parties and the commodity nature of laboratory sequencing prevent a Strong rating today.
- Moat direction: Strengthening. Oncology volume growth of 32% is feeding the data library faster than any direct competitor can match.
- Industry stage: Growth
- Industry growth estimate: ~15% annually in precision medicine and healthcare AI.
- Competitors: Guardant Health. GH. Focuses on liquid biopsy and early detection, directly competing with Tempus in the oncology clinic., Natera. NTRA. Dominates prenatal and MRD testing, representing a major hurdle for Tempus's expansion into cancer monitoring., Foundation Medicine. A subsidiary of Roche that provides high-quality genomic profiling for the same oncology customer base., Flatiron Health. Owned by Roche, they compete directly for the pharmaceutical data licensing contracts Tempus relies on for profit.
- Moat sources: Brand & IP. present, Switching Costs. partial, Network Effects
- Moat evidence: Gross margin: 66.5%, Oncology volume: 32% growth, Data bookings: >$550M YTD

### Industry
The precision medicine and healthcare AI market is roughly $50 billion today, growing at ~15% annually, and is on track to exceed $100 billion by 2030. This is an attractive industry because pharmaceutical companies are desperate to reduce the $2 billion cost of developing a new drug, and they will pay a premium for data that improves their odds of success. Tempus AI stands as a leader in this market because it controls both the laboratory where the data is created and the platform where it is analyzed, giving it a deeper library than pure software rivals.

### Competition
The market for healthcare data is rationally structured but requires immense scale to participate. Barriers to entry are high because building a federally regulated laboratory and integrating it with hospital software takes years of capital-intensive work. While laboratory testing itself is becoming more affordable, the ability to turn that testing into actionable AI insights is where the long-term pricing power lives.

Direct competitors include established genomic giants like Guardant Health and Natera, which are aggressively defending their turf in cancer monitoring and liquid biopsy. The most dangerous threat comes from "closed" data silos owned by large pharmaceutical companies like Roche, which owns both Foundation Medicine and Flatiron Health. These incumbents have deeper pockets and can bundle their testing services with their own drug portfolios to lock Tempus out of specific health systems.

Tempus AI is currently gaining share in the oncology market, evidenced by its 32% unit volume growth outpacing the broader industry's expansion.

### Moat
The primary source of protection for Tempus is its proprietary library of multimodal data, classified under Brand & IP. This library connects molecular data (DNA) with clinical outcomes (how the patient actually fared), which is incredibly difficult for rivals to collect at scale. The company has built a data flywheel where more clinical tests lead to more data, which leads to better AI models that attract more doctors.

The combination of 66.5% gross margins and accelerating oncology volume suggests that the laboratory business is a durable engine for data acquisition. While ROIC remains negative at -13.3%, this reflects the company's choice to spend heavily on R&D to widen its library rather than a lack of underlying profitability in the core tests. Lending is the same product wherever you get it, and a rival who sequences the same genes could undercut Tempus on price if the AI insights are not proven to be significantly better.

The moat is strengthening because the platform is successfully expanding into new disease areas like cardiology. This expansion proves that the Tempus "operating system" is not a one-trick pony, and the 300% growth in MRD volume shows it is successfully moving into the high-value monitoring market.

## Management

- CEO: Eric Lefkofsky
- Management rating: Strong
- Execution: High
- Execution evidence: Reached Adjusted EBITDA profitability in Q3 2026, ahead of internal timelines.
- Capital allocation: Adequate
- Capital allocation evidence: Agreed to acquire Personalis for $1.5B to secure MRD market leadership.
- Alignment: High
- Alignment evidence: Founder CEO Eric Lefkofsky holds a significant personal stake and voting control.
- Management decision: Strategic acquisition of Personalis to capture the minimal residual disease (MRD) monitoring market
- Management decision: Partnership with Bristol-Myers Squibb for $137.5M data licensing deal
- Management decision: Expansion into cardiology with two new FDA clearances for AI ECG models

Eric Lefkofsky is a proven founder-CEO with a history of building large-scale technology businesses, and his ability to steer Tempus toward profitability this quarter while maintaining high growth is impressive. Management has shown strategic judgment by moving beyond oncology into cardiology and cancer vaccines before the core oncology market becomes too crowded. Their ability to raise over $1.1 billion in total contract value provides significant visibility into future revenue, which is a hallmark of a leadership team that understands how to monetize data.

The primary risk is the high degree of key-person dependence on Lefkofsky, whose vision and ability to strike complex pharma deals are the engine of the company. While the company has a deep bench of technology and accounting leadership, the strategic direction is heavily founder-driven, and any change at the top would create immediate uncertainty. Additionally, the high concentration of revenue from Pathos AI, where Lefkofsky also has interests, requires careful governance oversight to ensure all deals are in the best interests of Tempus shareholders.

## Quality scorecard

Each business is scored 1 to 5 on what makes a company worth owning for the long term.

- Moat strength: 3 out of 5. The library of patient data is a significant asset, but laboratory sequencing remains a competitive and price-sensitive business.
- Capital efficiency: 2 out of 5. ROIC is currently -13.3%, reflecting heavy investment in R&D and lab infrastructure that has not yet reached full scale.
- Revenue growth: 5 out of 5. Revenue grew 83.4% last fiscal year and unit volume in oncology is accelerating at 32%, demonstrating massive market demand.
- Growth runway: 5 out of 5. Expansion into cardiology and cancer monitoring via Personalis more than doubles the company's addressable market beyond oncology.
- Management: 4 out of 5. Eric Lefkofsky has successfully navigated the path to adjusted profitability while striking critical high-value partnerships with pharma giants.
- AI resilience: 5 out of 5. The entire business model is built on using AI to extract value from clinical data, making the company a primary beneficiary of AI adoption.
- Risk resilience: 3 out of 5. Credit and reimbursement risks are managed well, but the heavy reliance on related-party revenue remains an untested governance vulnerability.

## Key numbers (as of November 3, 2026)

- Revenue over the last twelve months: $1.5 billion
- Revenue growth from a year earlier: 83.4%
- Average yearly revenue growth over five years: 49.0%
- Gross margin: 66.5%
- Operating margin: -19.9%
- Free cash flow margin: -4.4%
- Return on invested capital: -13.3%

## Fair value and verdict

Clearthesis also estimates Tempus AI's fair value, models what the stock could be worth over the next five years, and gives a verdict (whether it looks like a buy at today's price). Those are on the full thesis: https://www.clearthesis.ai/thesis/TEM?utm_source=ai_agent&utm_medium=markdown

Latest news and what it means for the thesis: https://www.clearthesis.ai/updates/TEM?utm_source=ai_agent&utm_medium=markdown

## Sources

- [SEC 10-K Annual Report](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=TEM&type=10-K&dateb=&owner=include&count=5), November 3, 2026
- [SEC 10-Q Quarterly Report](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=TEM&type=10-Q&dateb=&owner=include&count=5), November 3, 2026
- [Tempus Reports First Quarter 2025 Results | Tempus AI](https://investors.tempus.com/news-releases/news-release-details/tempus-reports-first-quarter-2025-results), November 3, 2026
- [Tempus Reports Fourth Quarter and Full Year 2024 Results | Tempus AI](https://investors.tempus.com/news-releases/news-release-details/tempus-reports-fourth-quarter-and-full-year-2024-results), November 3, 2026
- [Investor Relations | Tempus AI](https://investors.tempus.com), November 3, 2026
- [Earnings Press Release (2026-11-02)](https://www.sec.gov/Archives/edgar/data/1717115/000119312526442619/tem-ex99_1.htm), November 2, 2026
- [10-K (2025-12-31)](https://www.sec.gov/Archives/edgar/data/1717115/000119312526066961/0001193125-26-066961-index.htm), February 24, 2026
- [10-Q (2026-09-30)](https://www.sec.gov/Archives/edgar/data/1717115/000119312526442624/0001193125-26-442624-index.htm), November 2, 2026

Clearthesis research is for information and education only. It is not investment advice.
